S Vauterin

583 total citations
18 papers, 477 citations indexed

About

S Vauterin is a scholar working on Hematology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, S Vauterin has authored 18 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 5 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Surgery. Recurrent topics in S Vauterin's work include Platelet Disorders and Treatments (15 papers), Blood groups and transfusion (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). S Vauterin is often cited by papers focused on Platelet Disorders and Treatments (15 papers), Blood groups and transfusion (7 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). S Vauterin collaborates with scholars based in Belgium, Hungary and China. S Vauterin's co-authors include Hans Deckmyn, Karen Vanhoorelbeke, Nancy Cauwenberghs, Jolán Hársfalvi, Hans Ulrichts, Inge Pareyn, Muriel Meiring, Seb Lamprecht, Jan Roodt and Harry F. Kotzé and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

S Vauterin

17 papers receiving 469 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S Vauterin Belgium 12 360 124 88 84 65 18 477
K Horie Japan 8 370 1.0× 117 0.9× 106 1.2× 24 0.3× 82 1.3× 8 509
Koji Suzuki Japan 9 186 0.5× 77 0.6× 55 0.6× 72 0.9× 56 0.9× 11 343
Patricia A. Morateck United States 13 662 1.8× 97 0.8× 80 0.9× 153 1.8× 71 1.1× 19 741
P Hunt United States 6 448 1.2× 36 0.3× 73 0.8× 30 0.4× 103 1.6× 6 549
Maurits L. van Montfoort Netherlands 10 133 0.4× 183 1.5× 46 0.5× 77 0.9× 94 1.4× 24 439
Anne Schoolmeester Belgium 5 218 0.6× 73 0.6× 90 1.0× 50 0.6× 29 0.4× 5 325
Jeanne Pistillo United States 6 412 1.1× 150 1.2× 13 0.1× 46 0.5× 88 1.4× 12 571
PJ Newman United States 12 746 2.1× 95 0.8× 40 0.5× 138 1.6× 27 0.4× 17 833
F. Scheiflinger Austria 14 405 1.1× 224 1.8× 37 0.4× 22 0.3× 180 2.8× 25 594
Shinya Katsutani Japan 10 245 0.7× 48 0.4× 20 0.2× 56 0.7× 51 0.8× 21 334

Countries citing papers authored by S Vauterin

Since Specialization
Citations

This map shows the geographic impact of S Vauterin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Vauterin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Vauterin more than expected).

Fields of papers citing papers by S Vauterin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Vauterin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Vauterin. The network helps show where S Vauterin may publish in the future.

Co-authorship network of co-authors of S Vauterin

This figure shows the co-authorship network connecting the top 25 collaborators of S Vauterin. A scholar is included among the top collaborators of S Vauterin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Vauterin. S Vauterin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Szántó, Tímea, Ágota Schlammadinger, Steven Staelens, et al.. (2007). The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibα. Thrombosis and Haemostasis. 98(7). 178–185. 8 indexed citations
2.
Szántó, Tímea, Ágota Schlammadinger, Isabelle I. Salles, et al.. (2007). Type 2B von Willebrand disease in seven individuals from three different families: Phenotypic and genotypic characterization. Thrombosis and Haemostasis. 98(7). 251–254. 8 indexed citations
3.
Feys, Hendrik B., Fengzhen Liu, Ningzheng Dong, et al.. (2006). ADAMTS‐13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. Journal of Thrombosis and Haemostasis. 4(5). 955–962. 70 indexed citations
4.
Staelens, Steven, Michael A. Hadders, S Vauterin, et al.. (2005). Paratope Determination of the Antithrombotic Antibody 82D6A3 Based on the Crystal Structure of Its Complex with the von Willebrand Factor A3-Domain. Journal of Biological Chemistry. 281(4). 2225–2231. 24 indexed citations
5.
Ulrichts, Hans, Karen Vanhoorelbeke, JP Girma, et al.. (2005). The von Willebrand factor self-association is modulated by a multiple domain interaction. Journal of Thrombosis and Haemostasis. 3(3). 552–561. 40 indexed citations
6.
Ulrichts, Hans, S Vauterin, Simon F. De Meyer, et al.. (2005). How does agkicetin-C bind on platelet glycoprotein Ibα and achieve its platelet effects?. Toxicon. 45(5). 561–570. 20 indexed citations
8.
Feys, Hendrik B., Fang Liu, Ningzheng Dong, et al.. (2005). Newly Developed ADAMTS13 Antigen Assay Reveals Marked Ethnic Differences and Depletion in Acquired Thrombotic Thrombocytopenic Purpura.. Blood. 106(11). 1251–1251. 1 indexed citations
9.
Ulrichts, Hans, Karen Vanhoorelbeke, Sandra Cauwenberghs, et al.. (2003). Von Willebrand Factor But Not α-Thrombin Binding to Platelet Glycoprotein Ibα Is Influenced by the HPA-2 Polymorphism. Arteriosclerosis Thrombosis and Vascular Biology. 23(7). 1302–1307. 33 indexed citations
10.
Vanhoorelbeke, Karen, et al.. (2002). A Reliable von Willebrand Factor: Ristocetin Cofactor Enzyme-Linked Immunosorbent Assay to Differentiate between Type 1 and Type 2 von Willebrand Disease. Seminars in Thrombosis and Hemostasis. 28(2). 161–166. 14 indexed citations
11.
Vanhoorelbeke, Karen, Ágota Schlammadinger, S Vauterin, et al.. (2001). Occurrence of the Asn45Ser mutation in the GPIX gene in a Belgian patient with Bernard Soulier syndrome. Platelets. 12(2). 114–120. 14 indexed citations
13.
Cauwenberghs, Nicholas, et al.. (2001). Fc-receptor Dependent Platelet Aggregation Induced by Monoclonal Antibodies against Platelet Glycoprotein Ib or von Willebrand Factor. Thrombosis and Haemostasis. 85(4). 679–685. 15 indexed citations
14.
Cauwenberghs, Nicholas, Nadine Ajzenberg, S Vauterin, et al.. (2000). Characterization of Murine Anti-Glycoprotein Ib Monoclonal Antibodies That Differentiate between Shear-Induced and Ristocetin/Botrocetin-Induced Glycoprotein Ib-von Willebrand Factor Interaction. Pathophysiology of Haemostasis and Thrombosis. 30(3). 139–148. 11 indexed citations
16.
Cauwenberghs, Nancy, Muriel Meiring, S Vauterin, et al.. (2000). Antithrombotic Effect of Platelet Glycoprotein Ib–Blocking Monoclonal Antibody Fab Fragments in Nonhuman Primates. Arteriosclerosis Thrombosis and Vascular Biology. 20(5). 1347–1353. 105 indexed citations
17.
Vanhoorelbeke, Karen, et al.. (1999). A new and reproducible vWF : RiCof assay. Thrombosis and Haemostasis. 511–511. 5 indexed citations
18.
Depraetere, Hilde, et al.. (1998). Identification of Peptides, Selected by Phage Display Technology, That Inhibit von Willebrand Factor Binding to Collagen. Blood. 92(11). 4207–4211. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026